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7STUDY PROTOCOL Open AccessPerioperative use of crystalloids in patients
undergoing open radical cystectomy:
balanced Ringer’s maleate versus a glucose
5%/potassium-based balanced solution: study
protocol for a randomized controlled trial
Lukas M Löffel1, Bettina Kleeb1, Fiona C Burkhard2 and Patrick Y Wuethrich1*Abstract
Background: The optimal crystalloid solution to use perioperatively in patients undergoing open radical
cystectomy remains unclear. Many of the fluids used for intravenous hydration contain supraphysiologic
concentrations of chloride, which can induce hyperchloremia and metabolic acidosis, resulting in renal
vasoconstriction and decreased renal function. In addition, patients receiving less fluid and less sodium show faster
recovery of gastrointestinal (GI) function after colonic surgery.
Methods and design: This is an investigator-initiated, single-center, randomized, controlled, parallel group trial with
assessor-blinded outcome assessment, in the Department of Urology, University Hospital Bern, Switzerland. The study
will involve 44 patients with bladder cancer scheduled for radical cystectomy and urinary diversion. The
primary outcome is the duration between the end of surgery and the return of the GI function (first defecation).
Secondary outcomes are fluid balance (body weight difference postoperatively versus preoperatively) and the
incidence of kidney function disorders according to the Risk – Injury – Failure – Loss - End Stage Renal Disease
(RIFLE classification). An equal number of patients are allocated to receive Ringerfundin® solution or a glucose/
potassium-based balanced crystalloid solution as baseline infusion during the entire time that intravenous
administration of fluid is necessary during the perioperative period. The randomized crystalloid solution is infused at a
rate of 1 ml/kg/h until the bladder has been removed, followed by 3 ml/kg/h until the end of surgery. Postoperative
hydration is identical in both groups and consists of 1,500 ml of the randomized crystalloid solution per 24 hours.
Postoperative patient care is identical in both groups; patients are allowed to drink clear fluids immediately after
surgery, and liquid diet is started on postoperative day 1, as well as active mobilization and the use of chewing gum.
Body weight is measured daily in the morning. Time of first flatus and first defecation are recorded.
Discussion: This trial assesses the benefits and harms of two different balanced crystalloid solutions for perioperative
fluid management in patients undergoing open radical cystectomy with urinary diversion, with regard to return of GI
function and effects on postoperative renal function.
Trial registration: Current Controlled Trials ISRCTN32976792 (registered on November 21 2013).
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A recent randomized double-blind clinical trial has de-
monstrated that intraoperative restrictive hydration with a
maleate Ringer’s solution (Ringerfundin®) combined with
a concomitant norepinephrine infusion reduces the inci-
dence of postoperative complications and hospitalization
time [1]. Patients to whom restrictive hydration was
administered were more inclined to have a postoperative
zero fluid balance (i.e. weight difference on postoperative
day (POD) 1 versus preoperatively was 0) compared with
patients in the control group, who had a positive fluid
balance of approximately 2 kg on POD 1. A positive post-
operative fluid balance is known to be associated with
increased postoperative complications [2]. In addition, the
intraoperative use of norepinephrine, by minimizing the
risk of fluid overload, is associated with a lower incidence
of acute kidney damage [3].
Although enough evidence exists to support the rational
use of perioperative restrictive hydration, the choice of
the optimal crystalloid solution to use remains unclear,
and intravenous chloride administration is ubiquitous [4].
Many of the fluids used for intravenous hydration contain
supraphysiological concentrations of chloride, which can
induce hyperchloremia and metabolic acidosis, resulting
in renal vasoconstriction and decreased renal function [5].
The effect of chloride on the kidney is of concern because
acute kidney injury has been associated with high morta-
lity, and may require invasive renal replacement therapy
[6,7]. After administration of NaCl 0.9%, glucose 5% and
Ringer’s lactate solutions in normal subjects, the physio-
logical response is a slow excretion of sodium, which can
be impaired by hyperchloremia [8,9]. Because patients
undergoing cystectomy are prone to have transient cre-
atinine increase, electrolyte disturbance, and acidosis post-
operatively, it would make sense to administer a more
physiological intravenous solution to these patients perio-
peratively. In addition, it has been demonstrated that the
influence of salt and water balance on gastrointestinal (GI)
recovery after colonic surgery is clinically relevant: patients
receiving less fluid and less sodium show faster recovery of
GI function, resulting in a shorter hospitalization time
[10]. This is of crucial importance in patients undergoing
cystectomy because they are at risk for postoperative
constipation or ileus.
The aim of this study is to evaluate, in a prospective,
single-center, randomized, parallel-group, assessor-blinded
study design, the physiology of electrolyte and water
homeostasis in patients undergoing open radical cystec-
tomy and urinary diversion, using two different fluid regi-
mens. We hypothesize that an approach with a glucose/
potassium-based and reduced chloride crystalloid solution
will result in faster return of GI function, reduced hyper-
natremia and hyperchloremic metabolic acidosis, less
frequent hyperosmolality, and a better maintained fluidbalance compared with a regimen using a balanced
Ringer’s crystalloid solution.
Method and design
Ethics approval
The study was approved by the local ethics committee
(Kantonale Ethikkommission Bern KEKBE; chairperson:
Professor Dr N Tueller; registration number 151/13) on
October 22, 2013. This study is conducted in accordance
with the Declaration of Helsinki and was prospectively
registered on November 21, 2013 at http://www.controlled-
trials.com/isrctn with the trial identification number
ISRCTN32976792.
Objectives of the study
The main objectives of this study are 1) to analyze if a
positive salt and water balance is associated with a delayed
return of GI function; 2) to compare arterial pH, electro-
lyte (Na, K, Cl, Mg, HPO4), glucose, and bicarbonate con-
centrations at 6 h, 24, 48, 72 and 96 hours postoperatively;
3) to measure sodium and water excretion over the same
time period; 4) to study the effect of these crystalloid solu-
tions on plasma osmolality, levels of brain natriuretic
peptide (BNP), and plasma concentration of the hormones
controlling water and sodium excretion (plasma renin,
aldosterone, arginin-vasopressin); and 5) to measure the
urine osmolality and concentration of Na, Cl and neutro-
phil gelatinase-associated lipocalin (NGAL).
Study endpoints
The primary outcome variable is the postoperative
return of GI function after open radical cystectomy,
defined as the first defecation and expressed in days.
Secondary outcome variables are postoperative first flatus,
positive fluid balance (body weight difference postoperatively
versus preoperatively); incidence of kidney function dis-
orders according to the RIFLE classification [11]; difference
in pH 24 hours postoperatively (metabolic acidosis defined
as hyperchloremia, normal anion gap, low plasma bicarbon-
ate); changes in plasma and urine osmolality during the dur-
ation of infusion; incidence of hypernatremia during the
duration of infusion; incidence of hyperchloremia during
the duration of infusion; incidence of hypokalemia or hyper-
kalemia during the duration of infusion; changes in plasma
renin, aldosterone, arginin-vasopressin, and BNP levels; and
changes in NGAL urine values.
Study design
This is a prospective, single-center, randomized, parallel-
group, interventional, assessor-blinded trial conducted at
the Department of Urology of the Bern University Hospital,
Switzerland. We expect to randomize the first patient in
August 2014.
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Assessment of the endpoint data will be performed in a
blinded manner. The study nurse responsible for data
acquisition will not be allowed to see the content of the
crystalloid infusion. Laboratory, defecation, flatus, and
body weight data will be assessed electronically in the
nurse ward office using the CGM Phoenix Workstation
7-i-PDOS©; it will not be assessed in front of the patient.
Randomization will be carried out using a computer-
generated list with 11 blocks of 4 patients per block.
Allocation will be stored in sealed opaque and numbered
envelopes. Patients will be included strictly in numerical
order.
Selection of the participants
Consecutive patients with bladder cancer will be identi-
fied and recruited during the preoperative assessment of
eligibility for an open radical cystectomy with urinary
diversion. Participants fulfilling the inclusion criteria will
be asked for their signed informed consent as required
by the local ethics committee, and in accordance with
the Declaration of Helsinki.
Inclusion criteria are age ≥18 years old, type of surgery
(open radical cystectomy with urinary diversion; that is,
ileal conduit, orthotopic bladder substitute, catheteri-
zable ileal pouch), American Society of Anesthesiologists
(ASA) physical status II and III, and written informed
consent.
Exclusion criteria are pregnancy, breast-feeding (which
are exclusion criteria for this type of surgery itself ),
congestive heart failure (New York Heart Association
(NYHA) classification ≥3), severe hepatic disease (pro-
thrombin ratio <50%), and significant renal dysfunction
(estimated glomerular filtration rate <45 ml/min).
Time course of the study and collection of the data
Admission day
After informed consent, patients undergoing open radical
cystectomy with urinary diversion will be randomized,
according to the concealed numbered envelopes. Pre-
operative blood samples will be taken (plasma samples:
Na, K, Cl, Mg, HPO4, glucose, osmolality, renin, aldoster-
one, arginine-vasopressin, BNP; urine samples: NGAL,
Na, Cl and osmolality) and body weight documented. In
addition, preoperative American Society of Anesthesiolo-
gists (ASA) physical status score, Charlson comorbidity
score, and Glasgow prognostic score will be recorded.
Included patients will be requested to note the time of
first flatus and to inform the ward nurses accordingly.
During the first 5 postoperative days, patients will stay
on the intermediate care unit; this will allow rapid as-
sessment of the first flatus and defecation as patients will
be continuously monitored and will have at least one
visit by the nurse per hour. Assessment of the first flatusand defecation will be electronically documented (including
time of event).
6 h postoperatively
Blood samples will be taken (arterial blood gas analysis,
plasma samples: Na, K, Cl, Mg, HPO4, glucose, osmola-
lity, renin, aldosterone, arginine-vasopressin, BNP) as
well as urine samples of NGAL, Na, Cl and osmolality.
Postoperative day 1
Blood samples (arterial blood gas analysis, plasma samples:
Na, K, Cl, Mg, HPO4, glucose, osmolality, renin, aldoster-
one, arginine-vasopressin, BNP) and urine samples (NGAL,
Na, Cl and osmolality) will be taken. Body weight, fluid
balance (that is, difference between preoperative weight
and weight on postoperative day 1), and assessment of
flatus and defecation will be documented.
Postoperative days 2 to 4
On each of these days, blood samples (arterial blood gas
analysis, plasma samples: Na, K, Cl, Mg, HPO4, glucose,
osmolality, renin, aldosterone, arginine-vasopressin, BNP)
and urine samples (NGAL, Na, Cl and osmolality) will be
taken. Body weight and assessment of flatus and defecation
will be documented.
From postoperative day 5
Body weight and assessment of flatus and defecation will
be documented until return of the GI function (that is,
defecation) has occurred.
Figure 1 shows the CONSORT diagram of the trial.
Registration and record-keeping
All data will be collected and recorded onto case report
forms (CRFs) by a trained study nurse blinded to the
randomization group, which will be recorded onto a se-
cure electronic database in compliance with the new Swiss
federal law on research on human subjects (Human Re-
search Act, HFG/LRH) and related ordinances (KlinV/
OClin, HFV/ORH, and OV-HFG/Org LRH) and ICH-
GCP E6. Data assessment on CRF will be anonymous. In
accordance with Swiss law, all original records (CRF and
relevant correspondence) will be archived for 15 years in a
secure locked room in the Department of Urology, Bern
University Hospital, and then destroyed according to the
hospital standards concerning destruction of confidential
information. This will be carried out even if the trial is
terminated prematurely.
Data monitoring
External, independent monitoring will be performed on
site for quality control purposes by a study nurse trained
in data monitoring and recording, who will not be in-
volved in the study. This external monitoring will evaluate
Figure 1 CONSORT diagram. BE, base excess; FFP, fresh frozen plasma; MAP, mean arterial pressure; PRBC, packed red blood cell.
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completeness of the data recording (CRF). Two monito-
ring visits will be planned per year. Study data will be cen-
trally monitored by a study nurse (Department of Urology,
Bern University Hospital, Switzerland), who is not
involved in the recruitment or randomization of patients,
or assessment of the data. This study nurse will perform
source data verification for all patients, including written
informed consent, inclusion and exclusion criteria, and
study outcomes.Study intervention
An equal number of patients will be randomized to
receive either Ringerfundin® solution or G5-K crystalloidsolution as baseline infusion during the entire period
that an intravenous administration of fluid is necessary
(Table 1). The G5-K crystalloid solution is already used
as a baseline infusion on our intensive care unit, and has
been shown to be safe.Intraoperatively
After induction of anesthesia, a concomitant norepi-
nephrine infusion will be started at 2 μg/kg/h until
the end of surgery, and the randomized crystalloid so-
lution (Ringerfundin®; B Braun Medical AG, Sempach,
Switzerland) for group 1 or the G5-K solution for group 2
(Bichsel, Interlaken, Switzerland) will be infused at a rate
of 1 ml/kg/h until the bladder has been removed, followed
Table 1 Electrolyte composition of the two different
crystalloid solutions
Electrolyte Ringerfundin® G5-K solution
Sodium 145.0 mmol/l 50.0 mmol/l
Potassium 4.0 mmol/l 30.0 mmol/l
Magnesium 1.0 mmol/l 2.0 mmol/l
Calcium 2.5 mmol/l 0 mmol/l
Chloride 127.0 mmol/l 0 mmol/l
Acetate 24.0 mmol/l 0 mmol/l
Maleate 5.0 mmol/l 0 mmol/l
Lactate 0 mmol/l 18 mmol/l
HPO4 0 mmol/l 8.0 mmol/l
Glucose 0 mmol/l 50 g/l
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observed (mean arterial pressure (MAP) <60 mmHg),
norepinephrine will be titrated to a maximum of 8 μg/kg/h
after an initial bolus of 10 μg. If hypotension persists, a
bolus of 250 ml of balanced Ringer’s solution (Ringerfun-
din®) in both groups will be given.
In both groups, blood loss of >500 ml will be subs-
tituted with an equal amount of Ringerfundin®. Packed
red blood cells (PRBC) will be transfused if hemoglobin
values are less than 80 g/l (<100 g/l in patients with cor-
onary artery disease). Additional boluses of Ringerfun-
din® (250 ml) will be infused as a rescue medication if
MAP persists at less than 60 mmHg after the aforemen-
tioned correction, and in cases of severe intraoperative
metabolic acidosis (base excess < −5, pH <7.25) attribut-
able to severe hypovolemia.Postoperatively
Postoperative hydration will be identical in both groups,
and will consist primarily of 1,500 ml of the randomized
crystalloid solution per 24 hours [10]. If MAP is less
than 60 mmHg after a bolus of 500 ml of Ringerfundin®,
norepinephrine will be infused up to a rate of 200 μg/h
in both groups. PRBC units will be transfused according
to ASA guidelines [12], and fresh frozen plasma units
will be given if the prothrombin time is >1.5 times nor-
mal value.
In both groups, patients will be allowed to drink clear
fluids immediately after surgery while on the inter-
mediate care unit. An oral liquid diet will be started
on POD 1 and patients will begin active mobilization.
To enhance recovery of bowel function, patients will
be treated strictly according to our postoperative en-
hanced recovery protocol (Table 2). Use of chewing
gum will be encouraged [13], and the subcutaneous ap-
plication of neostigmine 0.5 mg will be started on POD2 (Table 2). Body weight will be measured daily in the
morning. Time of first flatus and first defecation will be
recorded.Statistics
Data will be analyzed by the research team in collabor-
ation with a medically versed biostatistician. There will
be no interim analysis.
Statistical analysis will be conducted on an intention-to-
treat basis. Data distribution will be tested by Q-Q plots.
Normally distributed data will be presented as mean and
standard deviation (SD), skewed data as median and range,
and dichotome data as number and percentage. Compar-
ing related and unrelated continuous samples, the paired
and unpaired t-tests, respectively, will be used for normally
distributed data and the Wilcoxon signed rank test and
Mann–Whitney U-test, respectively for skewed data. Dif-
ferences in proportions will be analyzed using the Fisher’s
exact test, and risk ratio with associated 95% confidence
interval (CI). For the analysis of the primary endpoint, we
will use the unpaired Student t-test with associated 95%
CI. In addition, a multiple logistic regression analysis will
be carried out, including the randomization groups and all
clinically relevant variables (age, ASA scores, Charlson co-
morbidity score, Glasgow prognostic score, postoperative
fluid balance). A two-sided P value of less than 0.05 will be
considered significant.Sample analysis
Based on retrospective data from our institution in the
same surgical population (mean duration until first de-
fecation 4.82 days, SD of 0.82 days), a power analysis was
performed using duration of return of GI function as the
primary variable. For a calculated sample size of 18 pa-
tients in each group (36 patients in total) the study is de-
signed to have an 90% power (β = 0.10) for the Wilcoxon/
Mann–Whitney test to detect a difference of 1 day be-
tween the groups (Ringerfundin® and G5-K solution) at a
two-sided significance level of 5% (α = 0.05) assuming an
SD of 1 day (G Power Version 3.1.5., Kiel and Duesseldorf,
Germany). This decrease of 1 day is considered clinically
relevant. Assuming a drop out of 20%, 22 patients per
group will be recruited.Assessment of safety
The methods used to measure plasma and urine samples
are those established at our hospital and used in everyday
clinical practice. Both intravenous solutions will be pro-
vided by the pharmacy of the University Hospital Bern.
Both solutions are routinely used at our institution (De-
partment of Anesthesia and Department of Intensive Care
Medicine).
Table 2 Study relevant information about enhanced recovery program for cystectomy patients at the University
Department of Urology, Bern (Cystectomy Enhanced Recovery Approach (CERA©))
Time points Interventions
Preoperative
No enteral bowel preparation
Two high enemas the evening before surgery
Normal nutrition till midnight before surgery
Clear drinks including carbohydrate till 2 h before surgery
Subcutaneous injection of low molecular heparin at 20:00 hours
Intraoperative
DVT prophylaxis with T.E.D.™ hose or sequential compression devices
Perioperative antibiotics 30 min before surgical incision
Restrictive fluid regimen aiming at zero postoperative weight gain
Gastrostomy tube placed, removal of orogastric tube at end of procedure
Postoperative
DVT prophylaxis with ambulation, T.E.D.™, and subcutaneous low molecular heparin (weight adapted), started 6 hours
postoperatively
Chewing gum encouraged
Clear drinks allowed the same evening after surgery
Gastrostomy tube initially left on drainage; closure of the gastrostomy tube will occur when patient is without nausea and vomiting
for >24 h
Bedside mobilization as soon as possible, ideally the same evening after surgery, but if this is not possible, not later than the next
morning
Initial pain treatment with thoracic epidural analgesia, no opioids
GI ulcer prophylaxis with esomeprazole for at least the first 2 POD
Antibiotics for 48 hours
Ambulation on POD 1
Start oral fluids including energy drinks (Ensure®, Impact®) on POD 1
Unrestricted clear drinks on POD 1
Prokinetics: start with 0.5 mg neostigmin subcutaneously up to 4 times per day on POD 2
Small snacks introduced on POD 2, not later than POD 3
POD 3: encourage longer mobilization, walking distances, and spending time in a chair
Anti-emetics given only on request
Drains removed if draining <50 ml/day
Gastrostomy tube removed once the patient has passed stool
POD 5: thoracic epidural removed, oral analgesics (metamizole, paracetamol, hydroxycodon/naloxon (Targin®))
DVT, deep vein thrombosis; POD, postoperative day; T.E.D.™, anti-embolism stockings by Covidien, Mansfield.
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Follow-up will be guaranteed because every patient in-
cluded in the trial will receive daily visits from the urolo-
gist in charge and will have blood samples taken. In
addition, all patients will be continuously monitored dur-
ing POD 1 to 5, as they will be on the intermediate care
unit.
The principal investigator (PYW) will monitor the pa-
tients for any adverse events (AEs), which are defined as
any unfavorable and unintended sign (including abnor-
mal laboratory results), symptom, or disease temporallyassociated with the use of the randomized infusions.
This will be documented on the CRF and immediately
communicated to the principal investigator.
Serious AEs (SAEs) are defined as any untoward medical
occurrence at any dose that results in death, or is life-
threatening (i.e. patient was at risk of death at the time of
the event), requires inpatient hospitalization or prolonga-
tion of existing hospitalization, or results in persistent or
significant disability/incapacity. All treatment related to
SAEs will be recorded and reported to the local ethics
committee. An investigation will be conducted, and a
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resumed, in accordance with the Good Clinical Practice
Guidelines of the Declaration of Helsinki.
Duration and timeline
The annual caseload of cystectomy is around 100 in our
institution per year. We expect to recruit our participants
within 18 months. The study protocol was designed and
approval from the local ethics committee obtained in
2013, and participants will be recruited during 2014
and 2015.
Discussion
The present study will improve knowledge on the use of
perioperative crystalloid solutions in patients with bladder
cancer undergoing radical cystectomy with urinary diver-
sion. This information should produce a basis on which to
develop strategies that aim to prevent perioperative
morbidity such as delayed return of the GI function and
postoperative renal dysfunction.
The primary outcome of this study is the return of GI
function, which is a cornerstone of the postoperative ma-
nagement of patients after major abdominal surgery.
Delayed return of GI function is one of the major reasons
for prolonged hospitalization time. The potential implica-
tions of our results are important. Accelerating the return
of GI function will inevitably shorten hospitalization time
and thus reduce the cost of hospital expenditure.
We expect by using the G5-K solution, which does not
contain chloride anions, to achieve not only a near-zero
water balance, as we already demonstrated in a previous
RCT, but also a near-zero salt balance after radical cys-
tectomy with urinary diversion [1]. In contrast we expect
the patients in the Ringerfundin® group to be at higher
risk of having a positive fluid and salt balance. This non-
accumulation of salts and water in the G5-K solution
group is expected to result in an earlier return of the GI
function. Lobo et al. already showed that a positive salt
and water balance after colonic resection delayed the
return of GI function and resulted in longer hospitalization
time. In addition, perioperative chloride loading is known
to impair urinary output, and to induce metabolic acidosis
and even hyperkalemia in patients with preoperative renal
dysfunction.
Conclusion
In conclusion, this trial is an investigator-initiated, prag-
matic, randomized clinical trial to test the hypothesis
that administration of glucose-rich balanced crystalloid
solution containing potassium can accelerate the return
of GI function. In addition, this study will also determine
the effect of this solution on renal function after radical
cystectomy with urinary diversion.Trial status
The trial is ongoing.
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